Aimmune Therap (AIMT)
$26.42 0.77 (3.00%)
19:57 EST AIMT Stock Quote Delayed 15 Minutes
Previous Close $26.42
Market Cap 1.53B
PE Ratio -8.78
Volume (Avg. Vol.) 1.27M
Day's Range 25.30 - 26.61
52-Week Range 16.95 - 37.00
Dividend & Yield N/A (N/A)
AIMT Stock Predictions, Articles, and Aimmune Therap News
- From InvestorPlace
- From the Web
Aimmune Therapeutics received FDA approval for its peanut allergy drug Palforzia, and AIMT stock could soar in 2020.
Which of our experts will win the best stocks contest? They're all betting on themes likely to dominate in 2020 and beyond.
With Palforzia awaiting final FDA approval, 2020 could be a big year for Aimmune Therapeutics. AIMT could be one of the best stocks.
This morning, I'm recommending a bullish call option on Aimmune Therapeutics, Inc. (NASDAQ:AIMT), the biopharmaceutical company.
Biotech stocks are off to a hot start in 2019, and these five stocks, in particular, could be the next winners.
3 Stocks to Watch on Tuesday: Aimmune Therapeutics Inc (AIMT), AnaptysBio Inc (ANAB) and SM Energy Co (SM)
Aimmune Therapeutics (AIMT), AnaptysBio (ANAB) and SM Energy (SM) all made headlines, with the first two developing peanut allergy medications with encouraging results.
From Seeking Alpha
From Analyst Ratings
Wedbush analyst Liana Moussatos reiterated a Buy rating on Aimmune Therapeutics (AIMT – Research Report) today and set a price target of $74.00. The company’s shares closed last Monday at $25.65. According to TipRanks.com, Moussatos ‘ ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -5.3% and a
Navellier RatingsPowered by Portfolio Grader